中药“祛白清髓汤剂”联合化疗治疗复发、难治性急性髓细胞白血病的临床研究
|
摘要
目的观察中药"祛白清髓汤剂"联合化疗治疗复发、难治性急性髓系白血病(AML-M4、AML-M5、AML-M7)类型的患者的临床疗效。方法采用随机对照方法。将符合纳入标准的60例复发、难治性急性髓系白血病患者分为A组(试验组)、B组(对照组)两组,每组30例。A组化疗后再给予中药"祛白清髓汤"治疗,B组单纯化学治疗,观察比较两组治疗前后的骨髓缓解率、血常规变化、感染发生率和不良反应发生情况。结果试验组获完全缓解14例、部分缓解5例,总缓解率63.33%;对照组获完全缓解9例、部分缓解3例,总缓解率40.00%,两组的骨髓总缓解率相比有统计学差异(P<0.05)。治疗后,试验组的白细胞和血小板数高于对照组,两者比较有统计学差异(P<0.05);在治疗后的感染发生率和不良发生情况相比较中,试验组低于对照组,两者间比较有统计学差异(P<0.05)。结论中药"祛白清髓汤剂"联合化疗复发、难治性急性髓系白细胞(AML-M4、AML-M5、AML-M7)类型的患者的临床疗效上与单纯化疗组有差异,且联合治疗更利于化疗后白细胞及血小板的恢复及减少感染及相关并发症的发生。
Objective To observe the clinical efficacy of traditional Chinese medicine " Qubai Qingsui Decoction" combined with conventional chemotherapy in the treatment of patients with relapsed and refractory acute myeloid leukemia( AML-M4, AML-M5, AML-M7). Methods A randomized controlled method was used. Sixty patients with relapsed and refractory AML who met the inclusion criteria were divided into two groups A group(test group) and B group(control group), 30 patients in each group. After treatment of group A with chemotherapy, the traditional Chinese medicine "Qubai Qingsui Decoction" was given. Group B was treated with chemotherapy alone. The bone marrow remission rate, blood routine changes, infection incidence and adverse reactions were observed before and after treatment. Results In the experimental group,14 cases were achieved complete remission and 5 cases were achieved patial remission. In the total remission rate was 63.33% in this group. In the control group, 9 cases were achieved complete remission and 3 cases were achieved partial remission. The total remission rate was 40.00%. The total remission rate between the two groups showed statistically significancy(P<0.05). After treatment, the number of white blood cells and platelets in the experimental group was higher than that in the control group, and there was a statistically significant difference between the two groups(P<0.05). In the comparison between the incidence of infection and the adverse events after treatment, the experimental group was lower than the control group. There was a statistically significant difference between the two groups(P<0.05). Conclusion The clinical efficacy of outcome traditional Chinese medicine "Qubai Qingsui Decoction" combined with chemotherapy for treatment of relapsed and refractory acute myeloid leukocytes(AML-M4, AML-M5, AML-M7) is better than that of chemotherapy used alone. Combination therapy is more conducive to the recovery of leukocytes and platelets after chemotherapy and reduce the incidence of infection and related complications.
Objective To observe the clinical efficacy of traditional Chinese medicine " Qubai Qingsui Decoction" combined with conventional chemotherapy in the treatment of patients with relapsed and refractory acute myeloid leukemia( AML-M4, AML-M5, AML-M7). Methods A randomized controlled method was used. Sixty patients with relapsed and refractory AML who met the inclusion criteria were divided into two groups A group(test group) and B group(control group), 30 patients in each group. After treatment of group A with chemotherapy, the traditional Chinese medicine "Qubai Qingsui Decoction" was given. Group B was treated with chemotherapy alone. The bone marrow remission rate, blood routine changes, infection incidence and adverse reactions were observed before and after treatment. Results In the experimental group,14 cases were achieved complete remission and 5 cases were achieved patial remission. In the total remission rate was 63.33% in this group. In the control group, 9 cases were achieved complete remission and 3 cases were achieved partial remission. The total remission rate was 40.00%. The total remission rate between the two groups showed statistically significancy(P<0.05). After treatment, the number of white blood cells and platelets in the experimental group was higher than that in the control group, and there was a statistically significant difference between the two groups(P<0.05). In the comparison between the incidence of infection and the adverse events after treatment, the experimental group was lower than the control group. There was a statistically significant difference between the two groups(P<0.05). Conclusion The clinical efficacy of outcome traditional Chinese medicine "Qubai Qingsui Decoction" combined with chemotherapy for treatment of relapsed and refractory acute myeloid leukocytes(AML-M4, AML-M5, AML-M7) is better than that of chemotherapy used alone. Combination therapy is more conducive to the recovery of leukocytes and platelets after chemotherapy and reduce the incidence of infection and related complications.
引文
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin,2013,63(1):11-3.
[2]王婕,郑丹丹,周永明.中药定清片联合化疗治疗急性白血病复发的临床研究[J].宁波大学学报(理工版),2017,30(03):97-101.
[3]张慧琪,杨宇佳.三氧化二砷联合全反式维甲酸治疗急性早幼粒细胞白血病的临床研究[J].中国现代医生,2018,56(25):105-108.
[4]杨向东,杨文华,史哲新,等.从白血病干细胞探讨中医中药治疗白血病的思路方法[J].现代肿瘤医学,2011,19(06):1250-1252.
[5]中华医学会血液学分会.复发难治性急性髓系白血病中国诊疗指南(2017年版)[J].中华血液学杂志,2017,38(03):183-184.
[6]张之南,沈悌.血液病诊断及疗效标准.第3版[M].北京:科学技术出版社,2007:131-131,271.
[7] NCCA. The NCCA Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology(Version 1.2019)[EB/OL]. Fort Washington:NC CA,2019[2019-01-18].
[8]吕鹏,张雅月,李蕊白,等.中医药在急性髓系白血病(非M3)围诱导化疗期的应用与研究进展[J].北京中医药,2017,36(10):955-959.
[9]王敬毅.中医药治疗急性白血病研究进展[A].中国中西医结合学会血液学专业委员会.第十一届全国中西医结合血液学学术会议暨第二届中西医结合血液高峰论坛论文集[C].中国中西医结合学会血液学专业委员会:中国中西医结合学会,2014:5.
[10]黄山.复方浙贝颗粒改善难治性急性白血病患者生存的临床观察[D].北京中医药大学,2011.
[2]王婕,郑丹丹,周永明.中药定清片联合化疗治疗急性白血病复发的临床研究[J].宁波大学学报(理工版),2017,30(03):97-101.
[3]张慧琪,杨宇佳.三氧化二砷联合全反式维甲酸治疗急性早幼粒细胞白血病的临床研究[J].中国现代医生,2018,56(25):105-108.
[4]杨向东,杨文华,史哲新,等.从白血病干细胞探讨中医中药治疗白血病的思路方法[J].现代肿瘤医学,2011,19(06):1250-1252.
[5]中华医学会血液学分会.复发难治性急性髓系白血病中国诊疗指南(2017年版)[J].中华血液学杂志,2017,38(03):183-184.
[6]张之南,沈悌.血液病诊断及疗效标准.第3版[M].北京:科学技术出版社,2007:131-131,271.
[7] NCCA. The NCCA Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology(Version 1.2019)[EB/OL]. Fort Washington:NC CA,2019[2019-01-18].
[8]吕鹏,张雅月,李蕊白,等.中医药在急性髓系白血病(非M3)围诱导化疗期的应用与研究进展[J].北京中医药,2017,36(10):955-959.
[9]王敬毅.中医药治疗急性白血病研究进展[A].中国中西医结合学会血液学专业委员会.第十一届全国中西医结合血液学学术会议暨第二届中西医结合血液高峰论坛论文集[C].中国中西医结合学会血液学专业委员会:中国中西医结合学会,2014:5.
[10]黄山.复方浙贝颗粒改善难治性急性白血病患者生存的临床观察[D].北京中医药大学,2011.